在心力衰竭中准
Filippos Triposkiadis1, Andrew Xanthopoulos2, John Skoularigis2
1School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus.
Journal of personalized medicine
|October 25, 2024
概括
心力衰竭 (HF) 的管理需要平衡 (Na+) 和水. 像23Na+MRI和可穿戴传感器这样的新方法可能会改善对HF患者Na+水平和拥堵的监测.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 生物医学工程 生物医学工程
背景情况:
- 心力衰竭 (HF) 受到 (Na+) 和水平衡中断的显著影响,导致液体保留和.
- 在HF患者中,不完整的脱血与较差的结果相关,突出显示需要有效的Na+向干预措施.
- 目前的HF管理通常涉及四重治疗,但优化Na+向治疗仍然是一个挑战.
研究的目的:
- 评估Na+向干预措施在心力衰竭患者的拥堵管理中的作用和有效性.
- 探索用于监测组织 (Na+) 和指导HF中Na+向治疗的先进方法.
- 调查高频中Na+储存的3个隔间模型的临床意义.
主要方法:
- 对高频率患者的Na+向干预措施 (饮食限制,高血压盐水,利尿剂) 现有文献的审查.
- 讨论新的监测技术,包括点尿,23Na+磁共振成像 (MRI) 和可穿戴传感器.
- 探索Na+储存的3个隔间模型,强调在皮肤等组织中非奥斯莫斯积累.
主要成果:
- 不完整的解压会对HF结果产生不利影响,这强调了有效的Na+和水平衡管理的重要性.
- 现有的高风严重程度指标在预测和管理拥堵方面存在局限性,可能导致失症.
- 新出现的证据表明,斑点尿可以指导Na+向干预措施,在急性和慢性HF.
- 23Na+-MRI和可穿戴传感器为准确的组织Na+量化和监测提供了有希望的途径.
结论:
- 优化Na+向干预措施对于接受四重治疗的选定HF患者至关重要.
- 先进的监测工具,如23Na+-MRI和可穿戴传感器,对于精确的组织Na+评估和指导治疗至关重要.
- 需要进一步的研究来阐明组织Na+储存的临床影响及其在HF发病率和死亡率中的作用.
更多相关视频
11:00Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
10.1K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.3K
相关概念视频
01:22Heart Failure Drugs: Diuretics
346
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346
01:29Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:26Heart Failure Drugs: Inotropic Agents
527
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
527
01:30Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
01:22Heart Failure VI: Adjunct Therapies
1
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
1